

Ranjana H Advani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3936977/publications.pdf>

Version: 2024-02-01

221
papers

23,712
citations

18465

62
h-index

7944

149
g-index

224
all docs

224
docs citations

224
times ranked

20146
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016, 127, 2375-2390.	0.6	5,965
2	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	13.9	1,449
3	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2013, 31, 88-94.	0.8	991
4	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015, 21, 922-926.	15.2	927
5	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2190-2196.	0.8	890
6	Ibrutinib in Previously Treated Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2015, 372, 1430-1440.	13.9	810
7	CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 1711-1721.	13.9	796
8	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2690-2697.	0.8	634
9	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , 2019, 393, 229-240.	6.3	517
10	Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 368, 1408-1416.	13.9	485
11	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016, 128, 2489-2496.	0.6	370
12	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015, 126, 739-745.	0.6	349
13	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. <i>Science Translational Medicine</i> , 2016, 8, 364ra155.	5.8	348
14	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2845-2853.	0.8	313
15	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood</i> , 2014, 123, 3095-3100.	0.6	280
16	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1183-1194.	0.6	276
17	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691.	0.8	256
18	Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. <i>Blood</i> , 2015, 125, 1394-1402.	0.6	242

#	ARTICLE	IF	CITATIONS
19	Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and SÅžary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. <i>Journal of Clinical Oncology</i> , 2015, 33, 3750-3758.	0.8	235
20	Stage I and II Follicular Non-Hodgkinâ€™s Lymphoma: Long-Term Follow-Up of No Initial Therapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 1454-1459.	0.8	211
21	A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2012, 18, 248-255.	3.2	204
22	Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 132, 40-48.	0.6	199
23	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. <i>Blood</i> , 2012, 120, 3280-3287.	0.6	188
24	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , 2019, 6, e254-e265.	2.2	184
25	Gene Expressionâ€‘Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 692-700.	0.8	176
26	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. <i>Blood</i> , 2017, 130, 2709-2717.	0.6	176
27	Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4371-4377.	0.8	175
28	A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous Tâ€‘cell lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 811-819.	1.2	172
29	Treatment recommendations from the Eighth International Workshop on WaldenstrÃ¶mâ€™s Macroglobulinemia. <i>Blood</i> , 2016, 128, 1321-1328.	0.6	161
30	Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2019, 37, 3359-3368.	0.8	161
31	Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 560-568.	0.6	157
32	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 ⁺ Peripheral T-Cell Lymphomas: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3137-3143.	0.8	153
33	Classical Hodgkin Lymphoma with Reduced Î²2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. <i>Cancer Immunology Research</i> , 2016, 4, 910-916.	1.6	146
34	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2014, 7, 24.	6.9	144
35	MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. <i>Clinical Cancer Research</i> , 2011, 17, 4125-4135.	3.2	126
36	Clonal architecture of CXCR4 and WHIM-like mutations in WaldenstrÃ¶m Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 172, 735-744.	1.2	122

#	ARTICLE	IF	CITATIONS
37	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.	0.6	117
38	Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. <i>Blood</i> , 2017, 129, 2519-2525.	0.6	115
39	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and ¹³⁷ Sr in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013, 161, 76-86.	1.2	111
40	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. <i>Blood</i> , 2021, 138, 427-438.	0.6	109
41	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	2.3	107
42	The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. <i>Cancer</i> , 2019, 125, 1507-1517.	2.0	106
43	Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. <i>Blood</i> , 2013, 121, 745-751.	0.6	105
44	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3015-3022.	0.8	102
45	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2021, 39, 1422-1437.e10.	7.7	102
46	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 565-575.	0.8	98
47	Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 912-918.	0.8	96
48	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	2.2	96
49	A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2014, 165, 358-363.	1.2	91
50	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012, 30, 3119-3126.	0.8	86
51	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	0.6	86
52	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	2.2	83
53	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL-2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20 ⁺ lymphoid malignancies. <i>British Journal of Haematology</i> , 2015, 170, 669-678.	1.2	80
54	Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1167-1176.	3.2	77

#	ARTICLE	IF	CITATIONS
55	Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. <i>Clinical Cancer Research</i> , 2018, 24, 4110-4118.	3.2	77
56	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 44.	6.9	76
57	Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine. <i>Leukemia and Lymphoma</i> , 2007, 48, 521-525.	0.6	73
58	Gray zone lymphoma with features intermediate between classical <sc>H</sc>odgkin lymphoma and diffuse large <sc>B</sc>â€cell lymphoma: <sc>C</sc>haracteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015, 90, 778-783.	2.0	71
59	A phase <sc>II</sc> study of cyclophosphamide, etoposide, vincristine and prednisone (<sc>CEOP</sc>) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral Tâ€cell lymphoma (<sc>PTCL</sc>): final results from the Tâ€cell consortium trial. <i>British Journal of Haematology</i> , 2016, 172, 535-544.	1.2	71
60	First-in-human phase I study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. <i>Oncotarget</i> , 2018, 9, 13023-13035.	0.8	70
61	A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C ?, administered as a 21-day infusion to patients with advanced ovarian carcinoma. <i>Cancer</i> , 2004, 100, 321-326.	2.0	65
62	A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. <i>Leukemia and Lymphoma</i> , 2013, 54, 1373-1379.	0.6	65
63	Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 111-121.	1.1	58
64	Brutonâ€™s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 121-133.	1.1	57
65	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. <i>Blood</i> , 2018, 131, 2120-2124.	0.6	56
66	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	0.6	53
67	Venetoclax in Previously Treated Waldenstrâ€™m Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	0.8	53
68	A prospective cohort study of patients with peripheral Tâ€cell lymphoma in the United States. <i>Cancer</i> , 2017, 123, 1174-1183.	2.0	51
69	Responseâ€adapted therapy for aggressive nonâ€Hodgkin's lymphomas based on early [18F] FDGâ€PET scanning: ECOGâ€ACRIN Cancer Research Group study (E3404). <i>British Journal of Haematology</i> , 2015, 170, 56-65.	1.2	50
70	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	0.6	50
71	Peripheral T cell lymphoma, not otherwise specified (PTCLâ€NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.	1.2	49
72	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	2.0	47

#	ARTICLE	IF	CITATIONS
73	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017, 58, 1607-1616.	0.6	46
74	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1100-1118.	0.4	46
75	How I treat nodular lymphocyte predominant Hodgkin lymphoma. <i>Blood</i> , 2013, 122, 4182-4188.	0.6	45
76	Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. <i>British Journal of Haematology</i> , 2018, 180, 164-166.	1.2	45
77	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	2.0	43
78	Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. <i>Clinical Cancer Research</i> , 2010, 16, 2167-2175.	3.2	42
79	Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. <i>Oncologist</i> , 2012, 17, 1073-1080.	1.9	42
80	Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. <i>Radiology</i> , 2016, 280, 220-229.	3.6	39
81	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 2569-2578.	0.6	36
82	Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). <i>Journal of Clinical Oncology</i> , 2015, 33, 740-748.	0.8	36
83	CD20-Targeted Therapy Ablates <i>De Novo</i> Antibody Response to Vaccination but Spares Preestablished Immunity. <i>Blood Cancer Discovery</i> , 2022, 3, 95-102.	2.6	36
84	A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refractory B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 182-182.	0.6	35
85	A Prospective Multicenter Study Of The Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2013, 122, 251-251.	0.6	34
86	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.	0.8	33
87	A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 848-848.	0.6	33
88	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	0.8	32
89	Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. <i>Blood</i> , 2012, 120, 60-60.	0.6	32
90	Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study. <i>Blood</i> , 2015, 126, 470-470.	0.6	31

#	ARTICLE	IF	CITATIONS
91	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 703-710.	0.6	29
92	How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1Âh: the Stanford Approach. <i>Molecular Imaging and Biology</i> , 2018, 20, 324-335.	1.3	29
93	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	2.5	29
94	Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 179-186.	1.1	28
95	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020, 25, 878-885.	1.9	28
96	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	2.5	28
97	Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 193-200.	0.2	27
98	Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. <i>Acta Haematologica</i> , 2020, 143, 40-50.	0.7	27
99	Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 718-720.	0.6	26
100	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 1718-1726.	3.2	26
101	Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 189, e86-e90.	1.2	25
102	Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). <i>Blood</i> , 2015, 126, 585-585.	0.6	25
103	Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkin's Disease: Mature Data in Early and Advanced Stage Patients.. <i>Blood</i> , 2004, 104, 308-308.	0.6	22
104	Optimal Therapy of Advanced Hodgkin Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 310-316.	0.9	21
105	Speeding up PET/MR for cancer staging of children and young adults. <i>European Radiology</i> , 2016, 26, 4239-4248.	2.3	20
106	Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 17-29.	1.2	19
107	Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020, 191, 44-51.	1.2	19
108	SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin's Lymphoma: Evidence of Antitumor Activity from a Phase I Study.. <i>Blood</i> , 2006, 108, 695-695.	0.6	19

#	ARTICLE	IF	CITATIONS
109	Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, e466-e468.	1.7	18
110	Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. <i>Blood</i> , 2019, 134, 238-238.	0.6	18
111	Assessment of Favorable (F) Versus Unfavorable (U) Early Stage Hodgkin's Disease (HD); the Stanford V + Radiotherapy (RT) Experience.. <i>Blood</i> , 2005, 106, 1932-1932.	0.6	17
112	Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin's Disease (NLPHD).. <i>Blood</i> , 2007, 110, 644-644.	0.6	17
113	Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1105-1105.	0.6	17
114	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. <i>Journal of the American College of Radiology</i> , 2014, 11, 1026-1033.e3.	0.9	16
115	Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. <i>Blood</i> , 2016, 128, 621-621.	0.6	16
116	Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8519-8519.	0.8	16
117	Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mucosa-Associated Lymphoid Tissue Lymphoma with Variable CD30 Expression. <i>Blood</i> , 2012, 120, 797-797.	0.6	15
118	Risk-adapted therapy for advanced-stage Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 200-206.	0.9	14
119	The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. <i>Blood</i> , 2011, 118, 442-442.	0.6	14
120	Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 1741-1741.	0.6	14
121	Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2014, 124, 3095-3095.	0.6	14
122	Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2016, 128, 104-104.	0.6	14
123	Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 99-106.	0.4	13
124	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). <i>Blood</i> , 2018, 132, 679-679.	0.6	13
125	Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2010, 116, 961-961.	0.6	13
126	A Phase II Trial of Ofatumumab in Subjects with Waldenström's Macroglobulinemia.. <i>Blood</i> , 2011, 118, 3701-3701.	0.6	13

#	ARTICLE	IF	CITATIONS
127	Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma. <i>Blood</i> , 2014, 124, 3092-3092.	0.6	13
128	Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. <i>Blood</i> , 2014, 124, 4453-4453.	0.6	13
129	A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 604-608.	0.6	12
130	Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K- γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. <i>Blood</i> , 2016, 128, 2979-2979.	0.6	12
131	Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. <i>Clinical Cancer Research</i> , 2022, 28, 1294-1301.	3.2	12
132	Management of Advanced Stage Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 241-247.	2.3	11
133	Stage I-IIA Non-Bulky Hodgkin's Lymphoma. Is Further Distinction Based on Prognostic Factors Useful? The Stanford Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1374-1379.	0.4	11
134	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	1.2	11
135	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 3623-3632.	2.5	11
136	Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. <i>Blood</i> , 2011, 118, 443-443.	0.6	11
137	Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results. <i>Blood</i> , 2018, 132, 2899-2899.	0.6	10
138	Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 543-54.	0.3	10
139	Cancer Vaccines and T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S97-S101.	2.0	9
140	Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 67-75.	0.4	9
141	Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). <i>Blood</i> , 2018, 132, 1635-1635.	0.6	9
142	A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results. <i>Blood</i> , 2012, 120, 2746-2746.	0.6	9
143	Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016, 128, 4144-4144.	0.6	9
144	First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 7503-7503.	0.8	9

#	ARTICLE	IF	CITATIONS
145	Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). <i>Oncotarget</i> , 2018, 9, 766-773.	0.8	8
146	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 192, 542-550.	1.2	8
147	¹⁸ F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2883-2893.	3.3	8
148	Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. <i>Blood</i> , 2019, 134, 468-468.	0.6	8
149	Phase II Study of Bortezomib in Waldenström's Macroglobulinemia: Results of WMCTG Trial 03-248.. <i>Blood</i> , 2005, 106, 490-490.	0.6	8
150	Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL). <i>Blood</i> , 2011, 118, 3711-3711.	0.6	8
151	Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia. <i>Blood</i> , 2015, 126, 1540-1540.	0.6	8
152	Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma. <i>Blood</i> , 2015, 126, 2706-2706.	0.6	8
153	Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 2984-2984.	0.6	8
154	Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8505-8505.	0.8	8
155	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2930-2930.	0.6	8
156	Risk stratification in extranodal natural killer/T-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1395-1405.	1.1	7
157	XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma. <i>Hematological Oncology</i> , 2015, 33, 90-95.	0.8	7
158	New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 626-636.	1.8	7
159	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. <i>Oncologist</i> , 2020, 25, e993-e997.	1.9	7
160	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018, 132, 1626-1626.	0.6	7
161	Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 649-649.	0.6	7
162	Customized Targeted Therapy in Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 105-122.	0.9	6

#	ARTICLE	IF	CITATIONS
163	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Archives of Pathology and Laboratory Medicine, 2016, 140, 1225-1227.	1.2	6
164	Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas. Blood, 2011, 118, 3091-3091.	0.6	6
165	Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. Blood, 2012, 120, 2745-2745.	0.6	6
166	Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. Blood, 2013, 122, 4386-4386.	0.6	6
167	First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.. Journal of Clinical Oncology, 2021, 39, 3006-3006.	0.8	5
168	Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. Blood, 2014, 124, 629-629.	0.6	5
169	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. Blood, 2016, 128, 2992-2992.	0.6	5
170	Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood, 2016, 128, 2993-2993.	0.6	5
171	Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2015, 33, 8506-8506.	0.8	5
172	Current Frontline Treatment of Diffuse Large B-Cell Lymphoma. Oncology, 2022, 36, 51-58.	0.4	5
173	Novel Approaches in Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 875-890.	0.9	4
174	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 655-655.	0.6	4
175	Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. Blood, 2011, 118, 94-94.	0.6	4
176	Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. Blood, 2014, 124, 1745-1745.	0.6	4
177	Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management. Blood, 2015, 126, 4860-4860.	0.6	4
178	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Blood, 2015, 126, 176-176.	0.6	4
179	Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. Blood, 2017, 130, 826-826.	0.6	4
180	Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2019, 134, 2022-2022.	0.6	4

#	ARTICLE	IF	CITATIONS
181	Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e376-e385.	1.8	3
182	Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Journal of Oncology Practice, 2017, 13, e673-e682.	2.5	3
183	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. Blood, 2011, 118, 1603-1603.	0.6	3
184	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. Blood, 2013, 122, 4277-4277.	0.6	3
185	Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. Blood, 2015, 126, 1536-1536.	0.6	3
186	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. Blood, 2021, 138, 878-878.	0.6	3
187	Reply to J. Wang et al. Journal of Clinical Oncology, 2019, 37, 755-757.	0.8	2
188	Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma. Nuclear Medicine Communications, 2021, 42, 792-799.	0.5	2
189	Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood, 2018, 132, 2937-2937.	0.6	2
190	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. Blood, 2012, 120, 1618-1618.	0.6	2
191	A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial. Blood, 2013, 122, 3044-3044.	0.6	2
192	Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.. Journal of Clinical Oncology, 2012, 30, 8070-8070.	0.8	2
193	Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d'Etude De Lymphome d'Adultes. Blood, 2013, 122, 3045-3045.	0.6	2
194	Bulky mediastinal classical Hodgkin lymphoma in young women. Oncology, 2014, 28, 253-6, 258-60, C3.	0.4	2
195	Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. Radiotherapy and Oncology, 2018, 129, 507-512.	0.3	1
196	Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study. JCO Oncology Practice, 2020, 16, e902-e911.	1.4	1
197	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). Blood, 2018, 132, 623-623.	0.6	1
198	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. Blood, 2019, 134, 2834-2834.	0.6	1

#	ARTICLE	IF	CITATIONS
199	The Clonal Architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. <i>Blood</i> , 2015, 126, 1486-1486.	0.6	1
200	Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 4758-4758.	0.6	1
201	Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2016, 128, 756-756.	0.6	1
202	The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. <i>Blood</i> , 2016, 128, 921-921.	0.6	1
203	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2838-2838.	0.6	1
204	Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4571-4571.	0.6	1
205	Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen. <i>Blood</i> , 2010, 116, 4828-4828.	0.6	0
206	Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. <i>Blood</i> , 2011, 118, 3068-3068.	0.6	0
207	Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8060-8060.	0.8	0
208	Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. <i>Blood</i> , 2012, 120, 4779-4779.	0.6	0
209	Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 643-643.	0.6	0
210	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8504-8504.	0.8	0
211	Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8544-8544.	0.8	0
212	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. <i>Blood</i> , 2014, 124, 1703-1703.	0.6	0
213	Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. <i>Blood</i> , 2015, 126, 2702-2702.	0.6	0
214	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018, 132, 93-93.	0.6	0
215	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. <i>Blood</i> , 2018, 132, 2861-2861.	0.6	0
216	A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. <i>Blood</i> , 2018, 132, 4157-4157.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. Blood, 2019, 134, 4027-4027.	0.6	0
218	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. Blood, 2019, 134, 1553-1553.	0.6	0
219	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. Blood, 2019, 134, 4026-4026.	0.6	0
220	PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy. Blood, 2020, 136, 17-18.	0.6	0
221	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. Blood, 2020, 136, 45-46.	0.6	0